| Literature DB >> 24067024 |
Arulkumar Nagappan1, Hyeon Soo Park, Kwang Il Park, Jin A Kim, Gyeong Eun Hong, Sang Rim Kang, Jue Zhang, Eun Hee Kim, Won Sup Lee, Chung Kil Won, Gon Sup Kim.
Abstract
BACKGROUND: Vitamin C (ascorbic acid) is an essential nutrient of most living tissues that readily acts as a strong reducing agent, which is abundant in fruits and vegetables. Although, it inhibits cell growth in many human cancer cells in vitro, treatment in cancer is still controversial. Hence, the purpose of this study was to investigate the molecular mechanism of the inhibitory effect of vitamin C on AGS cell growth, and protein profiles in AGS cells after exposure to vitamin C treatment, by using proteomic tools.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24067024 PMCID: PMC3848938 DOI: 10.1186/1471-2091-14-24
Source DB: PubMed Journal: BMC Biochem ISSN: 1471-2091 Impact factor: 4.059
Figure 1Effects of vitamin C on cell viability on AGS adenocarcinoma gastric cancer cell line. (A) The cells were exposed to vitamin C at the indicated dosages for 24 h and cell viability was determined. Vehicle-treated cells were arbitrarily set as 100% control viability. (B) Morphology of AGS cells treated with or without vitamin C for 24 h and examined by light microscopy (400). Results are expressed as the mean ± SD of three independent experiments (*P < 0.05; **P < 0.01, compared to control).
Figure 2Two-dimensional map of proteins from AGS gastric cancer cells treated with vitamin C. Proteins were isolated after exposure of the cells to A) control (only vehicle) and B) 300 μg/ml of vitamin C for 24 h and separated on IPG-strips with pH 4–7 in the first dimension, and then on 12% polyacrylamide gel on second dimension. The gels were silver stained.
Differentially expressed proteins in Vitamin C treated AGS cells identified by MALDI-TOF/MS
| 2 | TNIP2_HUMAN | TNFAIP3-interacting protein 2 | Q8NFZ5 | 49.24/91 | 6.03/5.83 | 56 | 15/7 | 2.3 |
| 3 | XIRP1_HUMAN | Xin actin-binding repeat-containing protein 1 | Q702N8 | 199.64/96 | 5.78/6.48 | 59 | 11/13 | 2.2 |
| 6 | TXND5_HUMAN | Thioredoxin domain-containing protein 5 | Q8NBS9 | 48.28/49 | 5.63/5.38 | 81 | 22/10 | 2.9 |
| 7 | CE290_HUMAN | Centrosomal protein of 290 kDa | O15078 | 290.89/28 | 5.75/6.04 | 69 | 9/16 | 8.5 |
| 8 | PRDX4_HUMAN | Peroxiredoxin-4 | Q13162 | 30.75/24 | 5.86/5.43 | 68 | 38/6 | 3.0 |
| 9 | CE290_HUMAN | Centrosomal protein of 290 kDa | O15078 | 290.89/23 | 5.75/5.21 | 60 | 8/15 | 6.4 |
| 1 | DPP3_HUMAN | Dipeptidyl peptidase 3 | Q9NY33 | 82.88/100 | 5.02/4.86 | 110 | 26/12 | 4.0 |
| 4 | DCTN2_HUMAN | Dynactin subunit 2 | Q13561 | 44.32/51 | 5.10/4.94 | 122 | 39/13 | 2.3 |
| 5 | IF4A1_HUMAN | Eukaryotic initiation factor 4A-I | P60842 | 46.35/48 | 5.32/5.31 | 175 | 47/17 | 2.1 |
| 10 | PSB6_HUMAN | Proteasome subunit beta type-6 | PSMB6 | 25.57/21 | 4.80/4.64 | 104 | 39/10 | 4.4 |
| 11 | EIF3K_HUMAN | Eukaryotic translation initiation factor 3 subunit K | Q9UBQ5 | 25.33/21 | 4.81/4.46 | 101 | 37/8 | 3.6 |
| 12 | PSA5_HUMAN | Proteasome subunit alpha type-5 | P28066 | 26.57/24 | 4.74/4.31 | 91 | 41/8 | 2.0 |
| 13 | IF6_HUMAN | Eukaryotic translation initiation factor 6 | P56537 | 27.10/23 | 4.56/4.13 | 86 | 50/7 | 3.8 |
| 14 | 1433Z_HUMAN | 14-3-3 protein zeta/delta | P63104 | 27.9/25 | 4.73/4.36 | 93 | 40/10 | 2.6 |
| 15 | 1433S_HUMAN | 14-3-3 protein sigma | P31947 | 27.87/25 | 4.68/4.26 | 150 | 58/12 | 2.2 |
| 16 | 1433E_HUMAN | 14-3-3 protein epsilon | P62258 | 29.33/26 | 4.63/4.27 | 131 | 93/12 | 2.3 |
| 17 | EF1B_HUMAN | Elongation factor 1-beta | P24534 | 24.92/26 | 4.50/4.12 | 130 | 50/11 | 3.3 |
| 18 | TPM4_HUMAN | Tropomyosin alpha-4 chain | P67936 | 28.62/27 | 4.67/4.28 | 94 | 25/10 | 3.1 |
| 19 | TPM3_HUMAN | Tropomyosin alpha-3 chain | P06753 | 32.86/27 | 4.68/4.37 | 95 | 20/11 | 2.7 |
| 20 | PCNA_HUMAN | Proliferating cell nuclear antigen | P12004 | 29.09/29 | 4.57/4.28 | 127 | 40/10 | 2.5 |
1Entry name, protein name and accession number from SWISS-PROT database identified by MALDI-TOF/MS.
2Theoretical molecular weight (kDa) and pI from SWISS-PROT database; the experimental values of pI and MW for every isoelectric spot were calculated using Progenesis samespots software (Nonlinear Dynamics Ltd., Newcastle, UK).
3Score is −10*log (p), where p is the probability that the observed match is a random event, Protein scores greater than 56 are significant (p<0.05).
Figure 3Enlargements of the 2-DE map of proteins from AGS gastric cancer cells treated with vitamin C, which displays corresponding sections of gels with protein spots derived from control and vitamin C treated cells. Three independent experiments were performed and the mean ± SD was plotted (*P < 0.05, **P < 0.01 compared with control).
Figure 4Effects of vitamin C on expression of 14-3-3 isoforms in AGS cells. Cells were treated with vitamin C (0 and 300 lg/ml) for 24 h. The cell lysates were subjected to SDS–PAGE and analyzed by Western blotting. Densitometric analyses of data were expressed as the mean ± SD of three independent experiments (*P < 0.05, **P < 0.01 compared with control).
Figure 5Flow diagram depicts the modulation of proteins expression due to inhibitory effect of vitamin C in AGS cells. Vitamin C down-regulated the 14-3-3 isoforms, cytoskeleton and associated proteins (TPM4 and TPM3), and up-regulated antioxidant proteins (PRDX4 and TXNDC5). The down-regulation of 14-3-3 proteins failed to maintain G2/M checkpoint which results in apoptosis. (↓ indicates down-regulation, ↑ indicates up-regulation).